CF
MBX

Corebridge Financial’s MBX Biosciences MBX Stock Holding History

Corebridge Financial’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,511
Closed -$40.7K – 2951
2025
Q1 		$40.7K Sell
5,511
-82
-1% -$867 ﹤0.01% 2784
2024
Q4 		$103K Buy
+5,593
New +$119K ﹤0.01% 2541

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Corebridge Financial's MBX Position: Q2 2025 in Review

Corebridge Financial sold out of MBX Biosciences (MBX) in Q2 2025, closing a stake of 5,511 shares — an estimated $40.7K sold.

Corebridge Financial first reported a position in MBX in Q4 2024 and held it in 2 quarters. The position peaked at $103K in Q4 2024. 88 funds tracked by Wall St. Rank hold MBX as of Q2 2025.

  • Corebridge Financial reported no remaining MBX Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 5,511 MBX Biosciences shares in Q2 2025, an estimated $40.7K.
  • Corebridge Financial first reported a position in MBX Biosciences in Q4 2024 and held it in 2 quarters.
  • Corebridge Financial's MBX Biosciences position peaked at $103K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.